TIVDAK

This brand name is authorized in United States.

Active ingredients

The drug TIVDAK contains one active pharmaceutical ingredient (API):

1
UNII T41737F88A - TISOTUMAB VEDOTIN
 

Tisotumab vedotin is an antibody-drug conjugate (ADC) directed to tissue factor (TF), a cell surface protein expressed at elevated levels on a variety of solid tumours relative to normal tissue. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Tisotumab vedotin binds to TF-expressing tumour cells, the ADC-TF complex is internalised, and local release of MMAE occurs via proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death.
 
Read more about Tisotumab vedotin

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 TIVDAK Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 TIVDAK Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01FX23 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 51144-003

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈